on the way to $1, page-18

Thanks, @Idfreedom,

Bigger market bigger opportunity that added $1 billion to Exacts market cap (Yes, $1 billion!!)

Also from a 'Tweeter': "EXACT Sciences (A$9.68B MC) Cologuard needs to be run off a faecal sample. Add to the cost at A$900, compared to <$100 for $RHYs ColoSTAT & it can be added to a panel of blood tests at an annual check-up without its own blood draw, ColoSTAT is likely to be a preferred test."

This why I like RHY... it has all the pillars to be successful, they just need to replicate performance in a larger trial later in the year. Then it is better than existing test (faecal vs blood test) and it is v v cheap relative to the comps... Both market cap and test cost wise viz Colvera (est $200m), Cologuard ($9 billion) etc.

All in all exciting times ahead and as your analysis points to @AMreidIt we are developing a tight register and should see selling dry up volume wise and a rerate shortly.

5x8's